CD155 promotes radioresistance and malignancy of esophageal cancer by regulating Hippo-YAP pathway

Abstract

The expression of CD155 has been observed to increase in various human cancers, but its role in the development of esophageal cancer (EC) is unclear. Radiotherapy is one of the primary therapeutic options for EC. However, radioresistance is still a severe issue in EC treatment. In this study, Oncomine database mining, immunohistochemistry, and survival analysis showed that higher expression of CD155 in patients with EC than in healthy controls. In vitro and in vivo, we found for the first time that irradiation increased the expression of CD155 in EC cells. CD155 knockdown inhibited cell proliferation and migration and tumor formation, and significantly increased radiosensitivity in EC. The in vivo model with high CD155 expression significantly promoted the proliferation and migration of EC cells. Furthermore, increased CD155 expression was associated with poor prognosis in patients with EC. CD155 regulated the Hippo-Yap pathway, influencing cell proliferation and migration. Therefore, CD155 is essential for the proliferation, migration, and radioresistance of EC. CD155 inhibition may be a viable strategy for improving radiation treatment efficacy in individuals with EC.

Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung (Review)

“…For instance, esophageal cancer cells strongly expressing TAZ survive longer than cells with reduced TAZ expression post-radiation ( 38 ). CD155 stimulates RR via modulation of YAP1 phosphorylation ( 39 ). Indeed, the overexpression of CD155 increases the quantity of nuclear YAP1, whereas its inhibition favors cytoplasmic localization ( 39 ).…”

“…CD155 stimulates RR via modulation of YAP1 phosphorylation ( 39 ). Indeed, the overexpression of CD155 increases the quantity of nuclear YAP1, whereas its inhibition favors cytoplasmic localization ( 39 ). A reduction in the expression of YAP1 and its target genes following catechol treatment sensitizes pancreatic cancer cells to irradiation ( 40 ).…”